Recro Pharma Company Profile (NASDAQ:REPH)

About Recro Pharma

Recro Pharma logoRecro Pharma, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing non-opioid therapeutics for the treatment of pain, initially for acute pain following surgery. The Company's lead product is an intranasal formulation of Dexmedetomidine (Dex). Its product candidates for pain indications include: Dex-IN, Dex-SL and Fadolmidine (Fado). Dex-IN is a product candidate under development for the treatment of post-operative pain and for the treatment of cancer breakthrough pain. Dex-SL is a product candidate for the treatment of chronic pain. Fado is a product candidate used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Company pursues as a topical product for local application to treat serious pain associated with nerve damage to local tissues (neuropathies), especially of the lower extremities, which can occur in diabetic patients.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: REPH
  • CUSIP:
Key Metrics:
  • Previous Close: $9.25
  • 50 Day Moving Average: $9.28
  • 200 Day Moving Average: $7.91
  • 52-Week Range: $5.59 - $12.86
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.00
  • P/E Growth: 0.00
  • Market Cap: $91.29M
  • Outstanding Shares: 9,869,000
  • Beta: -0.94
Profitability:
  • Net Margins: -8.70%
  • Return on Equity: -52.80%
  • Return on Assets: -13.16%
Debt:
  • Debt-to-Equity Ratio: 0.71%
  • Current Ratio: 2.85%
  • Quick Ratio: 2.31%
Additional Links:
Companies Related to Recro Pharma:

Analyst Ratings

Consensus Ratings for Recro Pharma (NASDAQ:REPH) (?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $21.75 (135.14% upside)

Analysts' Ratings History for Recro Pharma (NASDAQ:REPH)
Show:
DateFirmActionRatingPrice TargetDetails
9/16/2016Roth CapitalInitiated CoverageBuy$24.00View Rating Details
8/29/2016Janney Montgomery ScottInitiated CoverageBuy$21.00View Rating Details
8/11/2016Brean CapitalReiterated RatingBuy$28.00View Rating Details
7/18/2016HC WainwrightReiterated RatingBuyView Rating Details
4/14/2015MLV & Co.Boost Price TargetBuy$12.00 -> $22.00View Rating Details
12/9/2014AegisDowngradeBuy -> HoldView Rating Details
(Data available from 9/26/2014 forward)

Earnings

Earnings History for Recro Pharma (NASDAQ:REPH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/11/2016        
8/11/2016Q2($0.78)($0.83)$18.70 million$17.30 millionViewN/AView Earnings Details
5/12/2016Q1($0.66)($0.71)$13.00 million$17.70 millionViewN/AView Earnings Details
3/24/2016Q4($0.43)$1.13ViewN/AView Earnings Details
11/9/2015Q3($0.20)($0.24)ViewN/AView Earnings Details
5/13/2015Q115($0.52)($0.53)ViewN/AView Earnings Details
3/25/2015Q414($0.68)($0.45)ViewN/AView Earnings Details
11/10/2014Q314($0.51)($0.61)ViewN/AView Earnings Details
8/12/2014($0.25)($0.36)ViewN/AView Earnings Details
5/12/2014($0.36)($0.20)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Recro Pharma (NASDAQ:REPH)
Current Year EPS Consensus Estimate: $-3.13 EPS
Next Year EPS Consensus Estimate: $-2.31 EPS

Dividends

Dividend History for Recro Pharma (NASDAQ:REPH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Recro Pharma (NASDAQ:REPH)
Insider Ownership Percentage: 39.30%
Institutional Ownership Percentage: 36.38%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/16/2016Healthcare Master Fun BroadfinMajor ShareholderBuy390,000$7.50$2,925,000.00View SEC Filing  
5/31/2016Stewart MccallumInsiderBuy1,250$8.22$10,275.00View SEC Filing  
5/23/2016Randall MackVPBuy2,000$6.30$12,600.00View SEC Filing  
5/23/2016Scp Vitalife Partners (Israel)Major ShareholderSell2,503$6.30$15,768.90View SEC Filing  
5/20/2016Scp Vitalife Partners (Israel)Major ShareholderSell6,260$6.46$40,439.60View SEC Filing  
5/20/2016Winston J ChurchillDirectorSell58,331$7.91$461,398.21View SEC Filing  
5/19/2016Donna NicholsCAOBuy1,140$6.48$7,387.20View SEC Filing  
11/27/2015Scp Vitalife Partners Ii Lpmajor shareholderSell11,385$9.00$102,465.00View SEC Filing  
11/24/2015Scp Vitalife Partners (Israel)major shareholderSell4,393$9.00$39,537.00View SEC Filing  
7/7/2015Healthcare Master Fun BroadfinMajor ShareholderBuy646,553$11.60$7,500,014.80View SEC Filing  
6/8/2015Geraldine HenwoodCEOBuy4,500$8.92$40,140.00View SEC Filing  
6/5/2015Charles GarnerCFOBuy2,000$8.50$17,000.00View SEC Filing  
12/2/2014Healthcare Master Fun BroadfinMajor ShareholderBuy241,338$2.50$603,345.00View SEC Filing  
5/15/2014Charles GarnerCFOBuy3,000$6.69$20,070.00View SEC Filing  
5/15/2014Donna NicholsCAOBuy1,200$6.66$7,992.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Recro Pharma (NASDAQ:REPH)
DateHeadline
investornewswire.com logoShares Of Recro Pharma, Inc. (NASDAQ:REPH) Expected To Hit $28 - Investor Newswire (NASDAQ:REPH)
www.investornewswire.com - September 24 at 11:25 AM
4-traders.com logoRecro Pharma : Announces Pricing of Public Offering of Common Stock (NASDAQ:REPH)
www.4-traders.com - September 21 at 11:04 AM
News IconWhat are Brokerage Firms Saying About Recro Pharma, Inc. (NASDAQ:REPH)? - Frisco Fastball (NASDAQ:REPH)
friscofastball.com - September 19 at 11:34 AM
News IconStock Perspective: Recro Pharma, Inc. (NASDAQ:REPH) Company Earnings Watch - Frisco Fastball (NASDAQ:REPH)
friscofastball.com - September 18 at 6:31 PM
News IconAnalysts Take Aim At This Stock's Earnings Estimates: Recro Pharma, Inc. (NASDAQ:REPH) - Frisco Fastball (NASDAQ:REPH)
friscofastball.com - September 18 at 6:31 PM
finance.yahoo.com logoCoverage initiated on Recro Pharma by ROTH Capital (NASDAQ:REPH)
finance.yahoo.com - September 16 at 6:48 PM
News IconWhat are Research Firms Saying About Recro Pharma, Inc. (NASDAQ:REPH)? - Frisco Fastball (NASDAQ:REPH)
friscofastball.com - September 16 at 10:36 AM
News IconAnalysts Take: Recro Pharma, Inc. (NASDAQ:REPH) Projected Earnings & Price Targets - Frisco Fastball (NASDAQ:REPH)
friscofastball.com - September 15 at 7:06 PM
biz.yahoo.com logoRECRO PHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:REPH)
biz.yahoo.com - September 12 at 11:45 AM
globenewswire.com logoRecro Pharma Presents Clinical Data at PAINWeek 2016 - GlobeNewswire (press release) (NASDAQ:REPH)
globenewswire.com - September 8 at 10:52 AM
biz.yahoo.com logoRECRO PHARMA, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (NASDAQ:REPH)
biz.yahoo.com - September 8 at 10:52 AM
publicnow.com logoRecro Pharma Presents Clinical Data at PAINWeek 2016 (NASDAQ:REPH)
www.publicnow.com - September 7 at 7:10 PM
finance.yahoo.com logoRecro Pharma to Present at the Rodman & Renshaw 18th Annual Global Investment Conference (NASDAQ:REPH)
finance.yahoo.com - September 6 at 11:47 AM
capitalcube.com logoETF’s with exposure to Recro Pharma, Inc. : September 6, 2016 (NASDAQ:REPH)
www.capitalcube.com - September 6 at 11:47 AM
247wallst.com logo5 Speculative Biotech Analyst Stocks Under $10 With Massive Upside (NASDAQ:REPH)
247wallst.com - September 4 at 11:00 AM
News IconNotable Stocks in Focus: Astrotech Corp (NASDAQ:ASTC), Recro Pharma Inc (NASDAQ:REPH) - NYSE Journal (press release) (NASDAQ:REPH)
stockznews.com - August 24 at 6:49 PM
News IconShares Going Higher in Session: Recro Pharma, Inc. (NASDAQ:REPH) - Post News (NASDAQ:REPH)
www.kentuckypostnews.com - August 24 at 10:07 AM
bizjournals.com logoPHILADELPHIA: Pharma firm completes $15M public stock sale (NASDAQ:REPH)
www.bizjournals.com - August 22 at 11:42 AM
4-traders.com logoRecro Pharma : Announces Closing of Public Offering of Common Stock (NASDAQ:REPH)
www.4-traders.com - August 21 at 11:01 AM
globenewswire.com logoRecro Pharma Announces Closing of Public Offering of Common ... - GlobeNewswire (press release) (NASDAQ:REPH)
globenewswire.com - August 20 at 11:05 AM
investornewswire.com logoWill Recro Pharma, Inc. (NASDAQ:REPH) Hit $28 Price Target? - Investor Newswire (NASDAQ:REPH)
www.investornewswire.com - August 20 at 11:05 AM
bizjournals.com logoMalvern pharma firm completes $15M public stock sale (NASDAQ:REPH)
www.bizjournals.com - August 19 at 6:58 PM
publicnow.com logoRecro Pharma Announces Closing of Public Offering of Common Stock (NASDAQ:REPH)
www.publicnow.com - August 19 at 6:58 PM
finance.yahoo.com logoRECRO PHARMA, INC. Financials (NASDAQ:REPH)
finance.yahoo.com - August 19 at 10:03 AM
News IconRecro Pharma Inc. (REPH): Largest Shareholder Broadfin Capital Buys Even More Shares (NASDAQ:REPH)
feedproxy.google.com - August 18 at 2:16 PM
streetinsider.com logoRecro Pharma (REPH) Prices 1.99M Common Stock Offering at $7.50/Share (NASDAQ:REPH)
www.streetinsider.com - August 17 at 7:26 PM
4-traders.com logoRecro Pharma : Announces Proposed Public Offering of Common Stock (NASDAQ:REPH)
www.4-traders.com - August 17 at 7:26 PM
globenewswire.com logoRecro Pharma Announces Pricing of Public Offering of Common Stock - GlobeNewswire (press release) (NASDAQ:REPH)
globenewswire.com - August 17 at 10:05 AM
biz.yahoo.com logoRECRO PHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits (NASDAQ:REPH)
biz.yahoo.com - August 17 at 10:05 AM
streetinsider.com logoRecro Pharma (REPH) Prices 1.99M Common Stock Offering at $7.50/Share - StreetInsider.com (NASDAQ:REPH)
www.streetinsider.com - August 16 at 10:25 AM
News IconShares Seen Gapping Down Before the Bell: Recro Pharma, Inc. (NASDAQ:REPH) - Post News (NASDAQ:REPH)
www.kentuckypostnews.com - August 16 at 10:25 AM
globenewswire.com logoRecro Pharma Announces Proposed Public Offering of Common Stock - GlobeNewswire (press release) (NASDAQ:REPH)
globenewswire.com - August 16 at 10:25 AM
publicnow.com logoRecro Pharma Announces Pricing of Public Offering of Common Stock (NASDAQ:REPH)
www.publicnow.com - August 16 at 10:25 AM
publicnow.com logoRecro Pharma Announces Proposed Public Offering of Common Stock (NASDAQ:REPH)
www.publicnow.com - August 15 at 7:29 PM
capitalcube.com logoRecro Pharma, Inc. :REPH-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 (NASDAQ:REPH)
www.capitalcube.com - August 12 at 7:12 PM
biz.yahoo.com logoRECRO PHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial Stateme (NASDAQ:REPH)
biz.yahoo.com - August 12 at 7:12 PM
sg.finance.yahoo.com logoRecro Pharma reports 2Q loss (NASDAQ:REPH)
sg.finance.yahoo.com - August 11 at 10:22 AM
publicnow.com logoRecro Pharma Reports Second Quarter 2016 Financial Results (NASDAQ:REPH)
www.publicnow.com - August 11 at 10:22 AM
biz.yahoo.com logoRECRO PHARMA, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:REPH)
biz.yahoo.com - August 11 at 10:22 AM
marketexclusive.com logoA Look At Recro Pharma Inc (NASDAQ:REPH) And Alkermes Plc (NASDAQ:ALKS)'s Topline Triumph - Market Exclusive (NASDAQ:REPH)
marketexclusive.com - July 27 at 7:29 PM
bizjournals.com logoBunionectomy pain relief? Malvern firm may have a solution (NASDAQ:REPH)
www.bizjournals.com - July 27 at 10:09 AM
streetinsider.com logoRecro Pharma (REPH) Phase III Clinical Trial of IV Meloxicam Achieved Primary Endpoint (NASDAQ:REPH)
www.streetinsider.com - July 27 at 10:09 AM
4-traders.com logoRecro Pharma : Reports Positive Top-Line Results from Pivotal Phase III Clinical Trial of IV Meloxicam (NASDAQ:REPH)
www.4-traders.com - July 27 at 10:09 AM
rttnews.com logoRecro Pharma Inc. (REPH) Is Surging On Phase 3 Study Results (NASDAQ:REPH)
www.rttnews.com - July 27 at 10:09 AM
reuters.com logoRecro Pharma's intravenous painkiller succeeds in trial, shares soar - Reuters (NASDAQ:REPH)
www.reuters.com - July 26 at 7:30 PM
publicnow.com logoRecro Pharma Reports Positive Top-Line Results from Pivotal Phase III Clinical Trial of IV Meloxicam (NASDAQ:REPH)
www.publicnow.com - July 26 at 4:28 PM
investornewswire.com logoIs $28 Price Target Attainable For Recro Pharma, Inc. (NASDAQ:REPH)? - Investor Newswire (NASDAQ:REPH)
www.investornewswire.com - July 24 at 11:11 AM
news.cmlviz.com logoRecro Pharma Inc Stock Technicals at Critical Inflection Point - CML News (NASDAQ:REPH)
news.cmlviz.com - July 20 at 7:57 PM
News IconDo Institutional Investors Hate Recro Pharma (NASDAQ:REPH)? - Consumer Eagle (NASDAQ:REPH)
www.consumereagle.com - July 19 at 8:04 AM
News IconShares Experiencing a Downtrend: Recro Pharma, Inc. (NASDAQ:REPH) - TGP (NASDAQ:REPH)
telanaganapress.com - July 17 at 11:12 AM

Social

Recro Pharma (NASDAQ:REPH) Chart for Monday, September, 26, 2016


Last Updated on 9/26/2016 by MarketBeat.com Staff